Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
Explore this paper's citation graph
Summary
This review highlights key experimental and investigational therapies for NASH fibrosis, whose evaluation will be accelerated as new non-invasive markers of fibrosis are established.
- Type
- review
- Published
- 2021-03-18
- Cited by
- 20
- References
- 71
- Access
- Open access
- OpenAlex
- https://openalex.org/W3138288621
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:232353719
Keywords
Steatohepatitis, Hepatic stellate cell, Cirrhosis, Medicine, Fibrosis
References
- Assessment of treatment response in nonalcoholic steatohepatitis using advanced magnetic resonance imaging measures
- Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis.
- Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
- Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients
- Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.
- Cellular and molecular mechanisms of fibrosis
- Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice
- Role of FXR in regulating bile acid homeostasis and relevance for human diseases.
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
- Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma.
- The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo.
- Transient elastography for the diagnosis of liver fibrosis
- The Role of Cholesterol in the Pathogenesis of NASH.
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
- Fibroblast Growth Factor 21 Improves Hepatic Insulin Sensitivity by Inhibiting Mammalian Target of Rapamycin Complex 1 in Mice
- Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis
- Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
Cited by
- Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis
- Inflammatory and fibrotic mechanisms in NAFLD - implications for new treatment strategies
- Initiation of hepatic stellate cell activation extends into chronic liver disease
- Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse.
- Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation
- Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of a non-alcoholic steatohepatitis in mice.
- Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
- The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
- Niacin regresses collagen content in human hepatic stellate cells from liver transplant donors with fibrotic non-alcoholic steatohepatitis (NASH).
- RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
- Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
- Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells
- Invited review liver fibrosis in NAFLD/NASH: From pathophysiology towards diagnostic and therapeutic strategies.
- The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis
- Orphan receptor GPR176 in hepatic stellate cells exerts a profibrotic role in chronic liver disease
- Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β
- Harnessing nuclear receptors to modulate hepatic stellate cell activation for liver fibrosis resolution.
- B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration.
- Additional file 1 of RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
- RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
Related papers
- Research progress on the relationship between transforming growth factor-β1 and hepatic fibrosis
- Effectiveness of saponins from Panax notoginseng against hepatic fibrosis
- A Selective PPARγ Modulator Reduces Hepatic Fibrosis
- Non-Invasively Distinguishing Progress of Liver Fibrosis by Visualizing Hepatic Platelet Derived Growth Factor Receptor-Beta Expression with an MRI Modality in Mice
- Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets.
- Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats
- M1581 Anti-Copper Therapy Protects Against Hepatic Fibrosis By Down-Regulating Collagen Iα1 mRNA Expression in Hepatic Stellate Cells
- Hepatic cellular microenvironment:a novel drug target for anti-hepatic fibrosis
- Traditional Chinese medicine targets on hepatic stellate cells for the treatment of hepatic fibrosis: A mechanistic review
- Role of hepatic stellate cells in formation and regulation of hepatic fibrosis in schistosomiasis